Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma

Biomedicine and Pharmacotherapy

Volumn 62, Issue 3, 2008, Pages 139-146

  Rufini, Vittoria ^a   Castaldi, Paola ^a   Treglia, Giorgio ^a   Perotti, Germano ^a   Gross, Milton D ^b   Al Nahhas, Adil ^c   Rubello, Domenico ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Nuclear Medicine   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Diagnosis; Medullary thyroid carcinoma; Radiopharmaceuticals; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CALCITONIN; CALCITONIN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CHOLECYSTOKININ LIKE PEPTIDE; CHROMOGRANIN A MONOCLONAL ANTIBODY; DACARBAZINE; DOXORUBICIN; ETIDRONIC ACID TC 99M; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GASTRIN; HAPTEN; IODINE 131; LEVODOPA; MONOCLONAL ANTIBODY; OCTREOTIDE; PENTETATE INDIUM IN 111; PENTETATE OCTREOTIDE INDIUM IN 111; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ADJUVANT THERAPY; ASPIRATION BIOPSY; BIOCHEMISTRY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PALLIATIVE THERAPY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG UPTAKE; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE TRANSPORT; HUMAN; ISOTOPE LABELING; MINIMAL RESIDUAL DISEASE; NEUROFIBROMATOSIS; NUCLEAR MEDICINE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SIPPLE SYNDROME; THYROID GLAND; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PARAFOLLICULAR CELL; THYROID SURGERY; THYROIDECTOMY; TUMOR RECURRENCE;

3-IODOBENZYLGUANIDINE; ANIMALS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; HUMANS; IODINE RADIOISOTOPES; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SOMATOSTATIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 40749092887     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.07.011     Document Type: Review

References (90)

1. Giuffrida D., and Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 9 (1998) 695-701
2. Hazard J.B., Hawk W.A., and Crile Jr. G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 19 (1959) 152-161
3. Tagliabue M., Rossetto R., Cestino L., and Palestini N. Multiple endocrine neoplasia type 2. Biological and clinical aspects. Minerva Chir 59 (2004) 69-74
4. Ledger G.A., Khosla S., Lindor N.M., Thibodeau S.N., and Gharib H. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med 122 (1995) 118-124
5. Hubner R.A., and Houlston R.S. Molecular advances in medullary thyroid cancer diagnostics. Clin Chim Acta 370 (2006) 2-8
6. Moley J.F., and De Benedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229 (1999) 880-887
7. Fialkowski E.A., and Moley J.F. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94 (2006) 737-747
8. Collins B.T., Cramer H.M., Tabatowski K., Hearn S., Raminhos A., and Lampe H. Fine needle aspiration of medullary carcinoma of the thyroid. Cytomorphology, immunocytochemistry and electron microscopy. Acta Cytol 39 (1995) 920-930
9. Boi F., Maurelli I., Pinna G., Atzeni F., Piga M., Lai M.L., et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92 (2007) 2115-2118
10. Hodak S.P., and Burman K.D. The calcitonin conundrum: is it time for routine measurement of serum calcitonin in patients with thyroid nodules?. J Clin Endocrinol Metab 89 (2004) 511-514
11. Wu L.T., Averbuch S.D., Ball D.W., de Bustros A., Baylin S.B., and McGuire III W.P. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. Cancer 73 (1994) 432-436
12. Gilliam L.K., Kohn A.D., Lalani T., Swanson P.E., Vasko V., Patel A., et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 16 (2006) 801-810
13. Martins R.G., Rajendran J.G., Capell P., Byrd D.R., and Mankoff D.A. Medullary thyroid cancer: options for systemic therapy of metastatic disease?. J Clin Oncol 24 (2006) 1653-1655
14. Le H.N., and Norton J.A. Perspective on RET proto-oncogene and thyroid cancer. Cancer J 6 (2000) 50-57
15. Leboulleux S., Baudin E., Travagli J.P., and Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol 61 (2004) 299-310
16. Kebebew E., Ituarte P.H., Siperstein A.E., Duh Q.Y., and Clark O.H. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 (2000) 1139-1148
17. Barbet J., Campion L., Kraeber-Bodere F., Chatal J.F., and GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90 (2005) 6077-6084
18. Orlandi F., Caraci P., Mussa A., Saggiorato E., Pancani G., and Angeli A. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 8 (2001) 135-147
19. Pellegritti G., Leboullex S., Baudin E., Bellon N., Scollo C., Travagli J.P., et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Radiol 88 (2003) 1537-1542
20. Wang Q., Takashima S., Fukuda H., Takayama F., Kobayashi S., and Sone S. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 125 (1999) 842-848
21. Tung W.S., Vesely T.M., and Moley J.F. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118 (1995) 1024-1029
22. Szavcsur P., Godeny M., Bajzik G., Lengyel E., Repa I., Tron L., et al. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol 31 (2005) 183-190
23. Kebebew E., Kikuchi S., Duh Q.Y., and Clark O.H. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg 135 (2000) 895-901
24. Rufini V., Salvatori M., Garganese M.C., Di Giuda D., Maussier M.L., and Troncone L. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25 (2000) 273-282
25. 131I-iodobenzylguanidine. J Nucl Med 21 (1980) 349-353
26. 131I MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28 (1987) 979-988
27. Wafelman A.R., Hoefnagel C.A., Maes R.A., and Beijnen J.H. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21 (1994) 545-559
28. Solanki K.K., Bomanji J., Moyes J., Mather S.J., Trainer P.J., and Britton K.E. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG). Nucl Med Commun 13 (1992) 513-521
29. Troncone L., and Rufini V. MIBG in diagnosis of neuroendocrine tumors. In: Ell P.J., and Gambhir S.S. (Eds). Nuclear medicine in clinical diagnosis and treatment (vol. 1) (2004), Churchill Livingstone, Edinburgh 83-95
30. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-246
31. 123I-Metaiodobenzylguanidine uptake in the nape of the neck of children: likely visualization of brown adipose tissue. J Nucl Med 44 (2003) 1421-1425
32. Endo K., Shiomi K., Kasagi K., Konishi J., Torizuka K., Nakao K.I., et al. Imaging of medullary thyroid cancer with 131I-MIBG. [letter]. Lancet 2 (1984) 233
33. Sone T., Fukunaga M., Otsuka N., Morita R., Muranaka A., Yanagimoto S., et al. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine. J Nucl Med 26 (1985) 604-608
34. Baulieu J.L., Guillotteau D., Delisle M.J., Perdrisot R., Gardet P., Delépine N., et al. Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer 60 (1987) 2189-2194
35. 131I-Metaiodobenzylguanidine in the treatment of neural crest tumors. Proceedings of an International Workshop. Rome, Italy, September 6-7, 1991. J Nucl Biol Med 35 (1991) 177-183
36. Castellani M.R., Alessi A., Savelli G., and Bombardieri E. The role of radionuclide therapy in medullary thyroid cancer. Tumori 89 (2003) 560-562
37. 131I-MIBG therapy of neural crest tumours. [review]. Anticancer Res 17 (1997) 1823-1831
38. Castellani M.R., Chiti A., Seregni E., and Bombardieri E. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumors. Q J Nucl Med 44 (2000) 77-87
39. 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136 (2004) 1218-1226
40. Reubi J.C., Chayvialle J.A., Franc B., Cohen R., Calmettes C., and Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinoma. Lab Invest 64 (1991) 567-573
41. Papotti M., Kumar U., Volante M., Pecchioni C., and Patel Y.C. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol 54 (2001) 641-649
42. Baudin E., Schlumberger M., Lumbroso J., Travagli J.P., Caillou B., and Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81 (1996) 2541-2544
43. Kaltsas G., Korbonits M., Heintz E., Mukherjee J.J., Jenkins P.J., Chew S.L., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 (2001) 895-902
44. Wiseman G.A., and Kvols L.K. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 25 (1995) 272-278
45. Rufini V., Salvatori M., Saletnich I., Valenza V., Maussier M.L., Martino G., et al. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor. Q J Nucl Med 39 (1995) 140-144
46. Arslan N., Ilgan S., Yuksel D., Serdengecti M., Bulakbasi N., Ugur O., et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 26 (2001) 683-688
47. Dorr U., Sautter-Bihl M.L., and Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol 21 (1994) 42-45
48. Behr T.M., Gratz S., Markus P.M., Dunn R.M., Hufner M., Becker H., et al. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?. Eur J Nucl Med 24 (1997) 184-191
49. Behr T.M., and Becker W. Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin scintigraphy allow for prognostic prediction?. Eur J Nucl Med 26 (1999) 70-71
50. Gabriel M., Decristoforo C., Donnemiller E., Ulmer H., Watfah Rychlinski C., Mather S.J., et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 44 (2003) 708-716
51. Parisella M., D'Alessandria C., van de Bossche B., Chianelli M., Ronga G., Papini E., et al. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma. Cancer Biother Radiopharm 19 (2004) 211-217
52. Czepczynski R., Kosowicz J., Ziemnicka K., Mikolajczack R., Gryczynska M., and Sowinski J. The role of scintigraphy with the use of 99mTc-HYNIC-TOC in the diagnosis of medullary thyroid carcinoma. Endokrynol Pol 57 (2006) 431-435
53. Czepczynski R., Parisella M.G., Kosowicz J., Mikolajczack R., Ziemnicka K., Gryczynska M., et al. Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2007 May 26) [Epub ahead of print]
54. 123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 130 (2004) 649-656
55. Kaltsas G.A., Papadogias D., Makras P., and Grossman A.B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 12 (2005) 683-699
56. Waldherr C., Schumacher T., Pless M., Crazzolara A., Maecke H.R., Nitzsche E.U., et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a pilot study. Nucl Med Commun 22 (2001) 673-678
57. Bodei L., Handkiewicz-Junak D., Grana C., Mazzetta C., Rocca P., Bartolomei M., et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19 (2004) 65-71
58. Behr T.M., Gratz S., Markus P.M., Dunn R.M., Hufner M., Schauer A., et al. Anti-carcynoembrionic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcynoembrionic antigen and somatostatin receptor expression prognostic factors?. Cancer 80 (1997) 2436-2457
59. Busnardo B., Girelli M.E., Simioni N., Nacamulli D., and Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53 (1984) 278-285
60. Peltier P., Curtet C., Chatal J.F., Le Doussal J.M., Daniel G., Aillet G., et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 34 (1993) 1267-1273
61. Barbet J., Peltier P., Bardet S., Vuillez J.P., Bachelot I., Denet S., et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 39 (1998) 1172-1178
62. Chatal J.F., Campion L., Kraeber-Bodere F., Bardet S., Vuillez J.P., Charbonnel B., et al. Survival improvement in patients in medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24 (2006) 1705-1711
63. Mirallié E., Vuillez J.P., Bardet S., Frampas E., Dupas B., Ferrer L., et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 779-788
64. Stein R., Chen S., Reed L., Richel H., and Goldenberg D.M. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. Effectiveness of dacarbazine. Cancer 94 (2002) 51-61
65. Sharkey R.M., Hajjar G., Yeldell D., Brenner A., Burton J., Rubin A., et al. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibodies with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46 (2005) 620-633
66. Hellman D.E., Kartchner M., Van Antwerp J.D., Salmon S.E., Patton D.D., and O'Mara R. Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 48 (1979) 451-455
67. Deftos L.J., and Stein M.F. Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50 (1980) 967-968
68. Nusynowitz M.L., Pollard E., Benedetto A.R., Lecklitner M.L., and Ware R.W. Treatment of medullary carcinoma of the thyroid with I-131. J Nucl Med 23 (1982) 143-146
69. Saad M.F., Guido J.J., and Samaan N.A. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 57 (1983) 124-128
70. Erdogan M.F., Gursoy A., Erdogan G., and Kamel N. Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 27 (2006) 359-362
71. Cengic N., Baker C.H., Schutz M., Goke B., Morris J.C., and Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 90 (2005) 4457-4464
72. Ohta H., Yamamoto K., Endo K., Mori T., Hamanaka D., Shimazu A., et al. A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 25 (1984) 323-325
73. Guerra U.P., Pizzocaro C., Terzi A., Giubbini R., Maira G., Pagliaini R., et al. New tracers for the imaging of the medullary thyroid carcinoma. Nucl Med Commun 10 (1989) 285-295
74. Bombardieri E., Maccauro M., de Deckere E., Savelli G., and Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12 (2001) S51-S61
75. Siccardi A.G., Paganelli G., Pontiroli A.E., Pelagi M., Magnani P., Viale G., et al. In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting. Eur J Nucl Med 23 (1996) 1455-1459
76. Behr T., and Behe M.P. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 32 (2002) 97-109
77. Diehl M., Risse J.H., Brandt-Mainz K., Dietlein M., Bohuslavizki K.H., Matheja P., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28 (2001) 1671-1676
78. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11 (2004) 786-794
79. Khan N., Oriuchi N., Higuchi T., and Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 12 (2005) 254-260
80. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43 (2002) 66-71
81. Hoegerle S., Altehoefer C., Ghanem N., Brink I., Moser E., and Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28 (2001) 64-71
82. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 25 (2004) 439-443
83. Ong S.C., Schoder H., Patel S.G., Tabangay-Lim I.M., Doddamane I., Gonem M., et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48 (2007) 501-507
84. Adams S., Baum R.P., Hertel A., Schumm-Drager P.M., Usadel K.H., and Hor G. Metabolic (PET) and receptor (SPET) imaging of well-and less-differentiated tumours: comparison with expression of the Ki-67 antigen. Nucl Med Commun 19 (1998) 641-647
85. Beuthien-Baumann B., Strumpf A., Zessin J., Bredow J., and Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2007 Apr 14) [Epub ahead of print]
86. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88 (2003) 4083-4087
87. 18F)-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 88 (2003) 637-641
88. Maecke H.R., Hofmann M., and Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 46 (2005) 172S-178S
89. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33 (2006) 1115-1122
90. Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging 34 (2007) 982-993